Does zearalenone act like estrogen and matter more with high estradiol or hormone therapy?

Biological and mechanistic pathways

The physiological impact of zearalenone (ZEN), a non-steroidal mycoestrogen produced by Fusarium species, is driven by its ability to mimic endogenous hormones and engage estrogen receptor pathways:

• Estrogen receptor binding: ZEN directly binds to human estrogen receptor alpha (ERα) and beta (ERβ) with nanomolar affinity, exhibiting IC50 values of approximately 240 nM and 166 nM, respectively.
• Active metabolism: Once ingested, ZEN is metabolized into alpha-zearalenol ($\alpha$-ZEL), an even more potent compound that binds ERα with an IC50 of approximately 22 nM.
• Transcriptional activation: Upon binding, ZEN and $\alpha$-ZEL act as functional agonists, stimulating estrogen-responsive elements (EREs) to initiate gene transcription. ZEN acts as a full agonist at ERα, driving transcription in human HeLa cells with a low-nanomolar EC50 of approximately 24 nM, while $\alpha$-ZEL demonstrates transcriptional activity in the low picomolar range.
• Alternative signaling cascades: In addition to classical nuclear receptors, ZEN acts as an agonist at the membrane-bound G-protein-coupled estrogen receptor (GPER), initiating rapid non-genomic signaling pathways.

Clinical relevance to hormone-sensitive conditions

The biological actions of ZEN translate directly to tissue-level changes in individuals with sensitive clinical histories:

• Tissue proliferation: Estrogen signaling is the primary driver of uterine fibroids and fibrocystic breast disease. ZEN exposure is linked to endometrial hyperplasia, uterine swelling, and mammary hypertrophy in experimental models, demonstrating its capacity to stimulate these sensitive tissues.
• Compounding estrogenic burden: In an individual with elevated endogenous estradiol or one undergoing exogenous hormone therapy, ZEN does not block estrogen receptors; instead, it behaves as an additive agonist. This additional receptor activation lowers the threshold for cellular proliferation and tissue remodeling.
• Clinical history interactions: For patients with a history of uterine fibroids or fibrocystic breast changes, the presence of an additional, potent xenoestrogen alongside high baseline estradiol and hormone therapy is a clinically significant factor that can aggravate these benign, proliferative conditions.

Bottom line

• Elevated zearalenone represents a clinically relevant finding in patients with high estradiol, active hormone therapy, and a history of fibroids or fibrocystic breast disease. Because zearalenone and its highly active metabolite ($\alpha$-zearalenol) act as potent agonists at both classical estrogen receptors and GPER, they compound the overall estrogenic burden and can actively drive proliferation in hormone-sensitive tissues.